|
|
|
|
|
|
|
Dynavax Technologies (DVAX)
|
|
19.7 -0.4 (-1.99%)
|
04-18 16:00
|
|
Open:
|
20.1
|
Pre. Close:
|
20.1
|
|
High:
|
20.55
|
Low:
|
19.6
|
|
Volume:
|
1,553,452
|
Market Cap:
|
1215M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
20.576 - 20.676
|
20.676 - 20.775
|
|
Low:
|
19.312 - 19.435
|
19.435 - 19.556
|
|
Close:
|
19.473 - 19.667
|
19.667 - 19.859
|
|
|
|
Technical analysis (as of: 2018-04-18 4:39:45 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 26.63 One year: 31.10
|
|
Support:
|
Support1: 18.66  Support2: 16.10
|
|
Resistance:
|
Resistance1:
22.80 Resistance2: 26.63
|
|
Pivot:
|
19.43
|
|
Moving Averages:
|
MA(5): 19.83 MA(20): 19.30
MA(100): 17.89 MA(250): 15.59
|
|
MACD:
|
MACD(12,26):
0.56 Signal(12,26,9): 0.56
|
|
%K %D:
|
%K(14,3): 35.64 %D(3): 45.04
|
|
RSI:
|
RSI(14): 55.17
|
|
52-Week:
|
High: 24.45
Low: 5.15 Change(%): 251.8
|
|
Average Vol(K):
|
3-Month: 153200
10-Days 192119
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.DVAX has closed below upper band by 39.9%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-04-18T08:00:00-04:00
Your Daily Pharma Scoop: GW Pharmaceuticals' Epidiolex, Alnylam Data, Johnson & Johnson's Q1 Results
2018-04-18T06:21:19-04:00
Dynavax: Positive Results, Market Confusion
2018-04-17T11:46:21-04:00
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position
2018-04-16T15:40:18-04:00
Dynavax Tech's lead candidate combined with Keytruda shows positive action in early-stage studies
2018-04-16T12:05:10-04:00
Biotech Forum: The Week Ahead
2018-04-16T09:17:00-04:00
Premarket Gainers as of 9:05 am (04/16/2018)
2018-04-16T07:58:17-04:00
Investors bullish on early-stage data on Dyanvax's SD-101 + Keytruda in advanced melanoma; shares up 14% premarket
2018-04-16T07:50:03-04:00
Dynavax SD-101: Right Drug In The Wrong Combo
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
